{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-028676","form_type":"8-K/A","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.106561+00:00","generated_at":"2026-06-27T03:07:43.258924+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Hookipa restates Gilead deal, gets $35M equity; HIV R&D expanded","bullets":["Hookipa assumes additional HIV development responsibility under restated collaboration agreement.","Gilead to purchase up to $35 million of Hookipa common stock to support increased HIV R&D.","Restated agreement covers HBV and HIV vaccine programs using Hookipa's arenavirus technology.","Financial milestones and royalties are redacted but original 2018 deal amended.","Full collaboration agreement filed as Exhibit 10.1 to Form 8-K/A."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-028676","json":"https://secwatch.observer/filing/0001104659-22-028676.json","markdown":"https://secwatch.observer/filing/0001104659-22-028676.md","text":"https://secwatch.observer/filing/0001104659-22-028676.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922028676/0001104659-22-028676-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922028676/tm227839d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:07:43.258924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}